<div id="readability-page-1">Stock slump context: Pfizer’s shares are down over 50% from 2021 highs, hurt by post-COVID demand shifts and looming patent losses. Mixed analyst views: Consensus leans cautious with most ratings at hold, but price targets suggest potential double-digit upside. Pipeline in motion: Up to 20 pivotal studies are planned for 2026 as Pfizer works to offset revenue risks and regain growth momentum.</div>

ARKG

<p>Pfizer faces a split outlook as its stock has dropped over 50% from 2021 highs due to post-pandemic demand shifts and patent expirations. While analyst consensus remains cautious with mostly 'hold' ratings, price targets indicate potential double-digit upside. To counter revenue risks, Pfizer is advancing up to 20 pivotal studies scheduled for 2026 to restore growth momentum.</p>

- Pfizer's shares have declined over 50% from their 2021 highs due to changes in post-COVID demand and impending patent expirations.  
- Analysts maintain a cautious consensus, mostly rating the stock as hold, but price targets indicate a possible double-digit upside.  
- To counter revenue risks and stimulate growth, Pfizer has planned up to 20 pivotal studies for the year 2026.

Pfizer

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VG Health

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Health Care Select Sector SPDR

iShares US Pharma

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Pfizer faces split outlook as analysts weigh risks and recovery